Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

13.64
-0.2600-1.87%
Pre-market: 13.700.0600+0.44%04:07 EDT
Volume:939.29K
Turnover:12.91M
Market Cap:1.14B
PE:-4.30
High:14.02
Open:13.95
Low:13.35
Close:13.90
52wk High:19.11
52wk Low:3.91
Shares:83.43M
Float Shares:59.91M
Volume Ratio:0.72
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1700
EPS(LYR):-3.1667
ROE:-72.19%
ROA:-38.89%
PB:3.72
PE(LYR):-4.31

Loading ...

A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance

Simply Wall St.
·
13 hours ago

EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed

Simply Wall St.
·
Yesterday

EyePoint President and CEO Jay S. Duker acquires USD 19,724 of common shares

Reuters
·
Mar 17

EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus

TIPRANKS
·
Mar 17

EyePoint reports inducement grants under NASDAQ listing rule

TIPRANKS
·
Mar 16

EyePoint grants 20,000 inducement stock options at USD 13.2 per share

Reuters
·
Mar 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 16

EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating

TIPRANKS
·
Mar 10

EyePoint Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 09

EyePoint price target raised to $35 from $31 at Citi

TIPRANKS
·
Mar 09

EyePoint Pharma Bets Big on DuraVu in Pivotal Push

TIPRANKS
·
Mar 07

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Omada Health, Inc. (OMDA) and BridgeBio Oncology Therapeutics (BBOT)

TIPRANKS
·
Mar 06

Stock Track | EyePoint Plummets 13.78% Intraday on Insider Selling by Chief Medical Officer

Stock Track
·
Mar 06

EyePoint Chief Medical Officer Ramiro Ribeiro Disposes of Common Shares

Reuters
·
Mar 06

Guggenheim Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Mar 05

EyePoint Pharmaceuticals (EYPT) Gets a Buy from RBC Capital

TIPRANKS
·
Mar 05

Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating

MT Newswires Live
·
Mar 05

Buy Rating Backed by Margin Upside, Cost Savings, and CRM-Driven Growth Supporting $35 Price Target

TIPRANKS
·
Mar 05

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 05

EyePoint price target raised to $29 from $27 at Chardan

TIPRANKS
·
Mar 05